Challenges in the identification and use of rare disease-associated predisposition variants

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The case for identifying rare, disease-associated germline variants rather than undertaking larger genome-wide association (GWA) studies for common variants is increasingly being advocated. I agree with the importance of identifying rare variation in human disease, but believe more thought needs to be put into the limitations of such enterprises before advocating a dramatic departure from the GWA approach. In this paper, I discuss some of the main challenges in identifying rare disease variants with modest effects in disease, including: the overoptimistic expectations about their effects; the need for very large studies needed to prove, beyond doubt, statistical associations; the problems associated with private variants, including the need for functional studies; the difficulties in prioritisation of candidates for further validation and the issues related to the accurate estimation of the risk associated with individual rare variants. The rare variant approach is very promising, but it remains largely untested in comparison with the proven and successful GWA approach. Both strategies must continue to be pursued in parallel and their advantages and pitfalls must be considered without excessive scepticism or expectation.

Original languageEnglish (US)
Pages (from-to)277-281
Number of pages5
JournalCurrent Opinion in Genetics and Development
Volume20
Issue number3
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Rare Diseases
Genome
Genome-Wide Association Study

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology

Cite this

@article{a6aa272f317048378a02d3e26850c60c,
title = "Challenges in the identification and use of rare disease-associated predisposition variants",
abstract = "The case for identifying rare, disease-associated germline variants rather than undertaking larger genome-wide association (GWA) studies for common variants is increasingly being advocated. I agree with the importance of identifying rare variation in human disease, but believe more thought needs to be put into the limitations of such enterprises before advocating a dramatic departure from the GWA approach. In this paper, I discuss some of the main challenges in identifying rare disease variants with modest effects in disease, including: the overoptimistic expectations about their effects; the need for very large studies needed to prove, beyond doubt, statistical associations; the problems associated with private variants, including the need for functional studies; the difficulties in prioritisation of candidates for further validation and the issues related to the accurate estimation of the risk associated with individual rare variants. The rare variant approach is very promising, but it remains largely untested in comparison with the proven and successful GWA approach. Both strategies must continue to be pursued in parallel and their advantages and pitfalls must be considered without excessive scepticism or expectation.",
author = "Luis Carvajal-Carmona",
year = "2010",
month = "6",
doi = "10.1016/j.gde.2010.05.005",
language = "English (US)",
volume = "20",
pages = "277--281",
journal = "Current Opinion in Genetics and Development",
issn = "0959-437X",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Challenges in the identification and use of rare disease-associated predisposition variants

AU - Carvajal-Carmona, Luis

PY - 2010/6

Y1 - 2010/6

N2 - The case for identifying rare, disease-associated germline variants rather than undertaking larger genome-wide association (GWA) studies for common variants is increasingly being advocated. I agree with the importance of identifying rare variation in human disease, but believe more thought needs to be put into the limitations of such enterprises before advocating a dramatic departure from the GWA approach. In this paper, I discuss some of the main challenges in identifying rare disease variants with modest effects in disease, including: the overoptimistic expectations about their effects; the need for very large studies needed to prove, beyond doubt, statistical associations; the problems associated with private variants, including the need for functional studies; the difficulties in prioritisation of candidates for further validation and the issues related to the accurate estimation of the risk associated with individual rare variants. The rare variant approach is very promising, but it remains largely untested in comparison with the proven and successful GWA approach. Both strategies must continue to be pursued in parallel and their advantages and pitfalls must be considered without excessive scepticism or expectation.

AB - The case for identifying rare, disease-associated germline variants rather than undertaking larger genome-wide association (GWA) studies for common variants is increasingly being advocated. I agree with the importance of identifying rare variation in human disease, but believe more thought needs to be put into the limitations of such enterprises before advocating a dramatic departure from the GWA approach. In this paper, I discuss some of the main challenges in identifying rare disease variants with modest effects in disease, including: the overoptimistic expectations about their effects; the need for very large studies needed to prove, beyond doubt, statistical associations; the problems associated with private variants, including the need for functional studies; the difficulties in prioritisation of candidates for further validation and the issues related to the accurate estimation of the risk associated with individual rare variants. The rare variant approach is very promising, but it remains largely untested in comparison with the proven and successful GWA approach. Both strategies must continue to be pursued in parallel and their advantages and pitfalls must be considered without excessive scepticism or expectation.

UR - http://www.scopus.com/inward/record.url?scp=77953614624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953614624&partnerID=8YFLogxK

U2 - 10.1016/j.gde.2010.05.005

DO - 10.1016/j.gde.2010.05.005

M3 - Article

VL - 20

SP - 277

EP - 281

JO - Current Opinion in Genetics and Development

JF - Current Opinion in Genetics and Development

SN - 0959-437X

IS - 3

ER -